Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00857259 · ClinicalTrials.gov registry record · Phase 2
The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT00857259 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 16 participants.
The verdict
NCT00857259, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
The study will assess the safety and efficacy of Everolimus (RAD001) alone or in combination with Lucentis in patients with neo-vascular age related macular degeneration (AMD)
Interventions
- DRUG Everolimus
- DRUG Ranibizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00857259
The ClinicalTrials.gov registry entry for NCT00857259 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Everolimus is the first listed.
NCT00857259 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00857259 about?
NCT00857259 is a clinical study titled "The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration". The study will assess the safety and efficacy of Everolimus (RAD001) alone or in combination with Lucentis in patients with neo-vascular age related macular degeneration (AMD)
What is the current status of trial NCT00857259?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2009-02.
What interventions are being tested in trial NCT00857259?
The interventions under investigation include: Everolimus (DRUG), Ranibizumab (DRUG).
Who is sponsoring clinical trial NCT00857259?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.